期刊文献+

电脉冲化疗对人前列腺癌细胞系PC-3M的体外作用 被引量:3

Pingyangmycin(bleomycin A5)-mediated electrochemotherapy on human prostate cancer cell line PC-3M in vitro
原文传递
导出
摘要 目的 探讨电脉冲化疗对人前列腺癌细胞系PC 3M的体外作用。 方法 选用平阳霉素作为抗癌药物与电脉冲相结合 ,测定电脉冲化疗对PC 3M细胞系的细胞毒作用。HE染色法观察实验后形态学改变。 结果 单用平阳霉素 ,低浓度无效 ,高浓度有效 ,最大无细胞毒作用浓度为0 .1μg/ml;单用电脉冲 ,最大无细胞毒作用场强为 12 5V/mm ;平阳霉素与电脉冲相结合的电脉冲化疗最大无细胞毒作用浓度仅为单用平阳霉素的 1/ 10 0 ;0 .1μg/ml的平阳霉素与 12 5V/mm的场强相结合 ,细胞生存分数为 5 2 .6 % ,组织形态学改变明显。 结论 平阳霉素可显著被电脉冲增效 ,适用于电脉冲化疗 ;平阳霉素介导的电脉冲化疗对前列腺癌细胞生长有较强的抑制作用。 Objective To investigate the efficacy of electrochemotherapy with pingyangmycin (bleomycin A5) for the treatment of human prostate cell line PC 3M in vitro. Methods The prostate cancer cells were treated by pingyangmycin alone, electric pulse alone and by electrochemotherapy, i.e. electric pulses were delivered after pingyangmycin was given. Cytotoxicity was examined by MTT assay and histological examination. Results The maximum nontoxic dose for pingyangmycin was 0.1 μg/ml; The maximum voltage not showing cytotoxicity was 125 V/mm.The 50% inhibitory concentration was 100 times reduced in electrochemotherapy than pingyangmycin alone. Conclusions The cytotoxicity of pingyangmycin can be enhanced by electric impulses. Pingyangmycin may be a novel drug for electrochemotherapy.
出处 《中华泌尿外科杂志》 CAS CSCD 北大核心 2001年第2期86-88,共3页 Chinese Journal of Urology
关键词 前列腺肿瘤 电疗法 Prostatic neoplasms;Carcinoma;Electrotherapy
  • 相关文献

参考文献9

  • 1争光霉素协作组.平阳霉素治疗恶性肿瘤的临床疗效评价[J].中华肿瘤杂志,1979,1:172-174.
  • 2林赴田 李电东 等.平阳霉素的抗肿瘤作用与临床前药理研究[J].中华肿瘤杂志,1979,1(3):161-161.
  • 3Singh B N,Anticancer Drugs,1999年,10卷,139页
  • 4Mir L M,Br J Cancer,1998年,77卷,2336页
  • 5司徒镇强,细胞培养,1996年,138页
  • 6Mir L M,CR Acad Sci Ⅲ,1991年,313卷,613页
  • 7Mir L M,Eur J Cancer,1991年,27卷,68页
  • 8林赴田,中华肿瘤杂志,1979年,1卷,161页
  • 9争光霉素协作组,中华肿瘤杂志,1979年,1卷,172页

共引文献13

同被引文献22

  • 1张勇,陈维真,卢汉平,梁昌盛,刘长征.^(188)Re标记抗人前列腺癌单克隆抗体及其在荷瘤裸鼠体内的放射性分布[J].核技术,2007,30(8):699-701. 被引量:4
  • 2孙辉,王金国,付言涛,何尔斯泰.小鼠肌肉内绿色荧光蛋白基因电转染[J].吉林大学学报(医学版),2005,31(2):239-242. 被引量:2
  • 3张勇,陈维真,谢瑶,姚志彬,温星桥.反基因及反义寡核苷酸体外抗前列腺癌作用的研究[J].中华泌尿外科杂志,2005,26(7):472-475. 被引量:4
  • 4Manabe Y, Tsubota T, Haruta Y, et al. Production of a monoclonal antibody-bleomycin conjugate utilizing dextran T-40 and the antigen-targeting cytotoxicity of the conjugate [ J ]. Biochcm Biophys Res Commun, 1983, 115: 1009-14.
  • 5Hamblett KJ, Senter PD, Chace DF, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate [J]. Clin Cancer Res, 2004, 10: 7063-70.
  • 6Armstrong A J, Carducci MA. Advanced prostate cancer: the future [J]. Can J Urol, 2005, 12(s2): 42-7.
  • 7Manabe Y, Tsubota T, Haruta Y, et al. Production of a monoclonal antibody-bleomycin conjugate utilizing dextran T-40 and the antigen-targeting cytotoxicity of the conjugate [J]. Biochem Biophys Res Commun, 1983,115(3):1009-1014.
  • 8Hamblett K J, Senter PD, Chace DF, et al. Effects of drug loading on the antitumor activity of a mono-clonal antibody drug conjugate [J]. Clin Cancer Res, 2004,10 (20):7063-7070.
  • 9Armstrong A J, Carducci MA. Advanced prostate cancer: the future [J]. Can J Urol, 2005, 12(s2): 42-47.
  • 10Keane TE, Rosner IL, Wingo MS, et al. The emergence of radioimmunoscintigraphy for prostate cancer [J]. Rev Urol, 2006, 8(Suppl 1):S20-28.

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部